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Biomarkers for Individual Susceptibility to
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In rats exposed to a single intraperitoneal dose of 200 mg/kg of the environmental carcinogen benzo[aI-
pyrene (BP) in sunflower oil, significant individual variations in excretion ofthe BP activation (BP-7,8-diol)
anddeactivation (3-OH-BP) derivatives werefound.Mostratsdevelopedperitoneal sarcomas.Onlythelevelsof
BP-7,8-diol excreted in the urine correlated directly with the latency of tumor formation. After a similar
exposure toadoseof100 mg/kgBP,Macacafascicularis monkeysexcreted smallerquantitiesthanrats ofboth
metabolites. After rats were given 10 intraperitoneal injections each of 10 mg/kg of BP in a water-lipid
emulsion,theexcretedlevels ofboth metabolites afterthefirst,fifth,andtenthinjectionwerelowerthanthose
ofthe ratsthatreceived 200 mg/kg. BP metabolites were alsodetected inthe urine oflungcancerpatients who
were heavy smokers. The applicability of monitoring the excretion of the BP metabolites to predicting
individual cancer risk is discussed.
rats was also compared with that in monkeys, as they are
Introduction mostrelevant to the human situation.
The susceptibility markers thatwe are currently devel-
oping for predicting individual human response to car-
cinogenic exposures include the following end points: a)
endogenous formation of carcinogens (1), b) excretion of
metabolites ofcarcinogens (2), and c) formation ofadducts
of carcinogens with various cellular targets, predomi-
nantly DNA, and efficiency of DNA repair (3,4).
In this communication, wepresentrecent datathatmay
contribute to the development of markers of individual
susceptibility to a powerful environmental carcinogen,
benzo[a]pyrene (BP). In rats, we have monitored excretion
ofits activation (BP-7,8-diol) and deactivation (3-OH-BP)
derivatives and studied the correlation between individual
patterns of metabolite excretion and the carcinogenic
effect ofBP. The pattern ofexcretion ofBP metabolites in
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Materials and Methods
Experiments werecarried outonmaleoutbred LIO rats
(5), weighing approximately 150 g, and male Macacafas-
cicularis monkeys weighing 4-6 kg. Group 1 (19 rats)
received a single intraperitoneal injection of BP in sun-
flower oil at a dose of200 mg/kg; group 2 (4 rats) and five
monkeysreceived adoseof100mg/kg.Afterexposure, the
animals were placed in individual metabolic cages, and
feces and urine were collected daily for 5-30 days (see
Table 1) on ice and stored at -4°C. BP-7,8-diol and 3-OH-
BP were extracted from urine and feces according to a
modification of the technique of Camus et al. (6) on an
Amberlite XAD-2 column, deconjugated and quantified
spectrofluorimetrically (7). Rats in group 1 were main-
tained to monitor the development of tumors. Group 3,
consisting of 10 rats which are currently under observa-
tion for tumor development, were given 10 intraperitoneal
injections of a water-lipid emulsion of BP at a dose of 10
mg/kg, with 10-day intervals between injections, and BP
metabolites were quantified in the excreta after the first,
fifth, and tenth injections.LIKHACHEV ET AL.
Individual patterns of BP metabolite excretion and
tumor latency in rats in group 1 were correlated using the
parametric approach ofregression analysis. The relation-
ship between quantities of excreted BP metabolites and
tumor latency was also evaluated by a modification of
Kaplan-Meier analysis (8).
Results
Individual and Species-Specific
Peculiarities ofBP Metabolite Excretion
Peak concentration of both metabolites were observed
in rats of group 1 (Table 1) 2-3 days after exposure,
followed by a slow decrease: by 30 days after exposure,
neither metabolite was found in the excreta. Both BP
metabolites were excreted predominantly with the feces.
Individual variations in total excretion of BP metabolites
over5,8, and 15 days were considerably smallerthan daily
variations.
Strong correlations were observed only between fecal
excretion ofBP-7,8-diol and 3-OH-BP and between excre-
tion of3-OH-BPinurineandfeces (correlation coefficients
ranged from 0.67 to 0.91). The mechanisms of this phe-
nomenon and its possible biological significance are
unclear.
Aftermultiple exposures to alowerdoseofBP(group3),
the levels of excreted BP metabolites were lower than
those of rats in group 1, decreasing progressively with
progressive doses. This result may be due to an age-
associated decrease in the activity of drug-metabolizing
enzymes (9) and/or exhaustion of these enzymes by the
preceding exposures.
Monkeys were weaker metabolizers ofBP than rats: in
monkeys, the total excretion ofBP-7,8-diol in feces over 5
daysrangedfrom14.6to48.5 pug/kgbodyweight(mean =
29.4), and that of 3-OH-BP from 0.8 to 1.8 (mean = 1.2),
whereas in the rats the corresponding values were 79.9-
163.6 (mean = 17.5) and 14.0-25.2 (mean = 21.8). The
ratio of BP-7,8-diol to 3-OH-BP in the feces of monkeys,
however, was as much as 5-6 times higherthan thatin the
rats.
Comparisons of Individual Patterns of BP
Metabolite Excretion in Rats Exposed to a
Single Dose ofBP and Its Subsequent
Carcinogenic Effect
In rats of group 1, the first tumor was observed on day
123 after exposurein one of16 rats thatsurvived this long.
Tenratsdevelopedperitonealtumorswithlocaldissemina-
tion, all of which appeared to be malignant fibrous his-
tiocytomas. The individual patterns of total excretion of
BP metabolites over 5 days after exposure and tumor
latency (time ofdeath) are presented in Table 2. Maximal
correlations between BP metabolite excretion and tumor
latency were detected with an exponential model for total
excretion of BP-7,8-diol over 5 days in urine (Table 3).
Evaluation ofthe probability oftumor appearance during
the period ofobservation on the basis ofthe quantities of
excreted metabolites if highly approximative because of
Table 1. Excretion ofbenzo[a]pyrene (BP) metabolites (,ug/kg body weight) by rats exposed intraperitoneally to BP.
Urine Feces Days
after BP-7,8-diol 3-OH-BP BP-7,8-diol 3-OH-BP
Group exposure Mean ± SEM Range Mean ± SEM Range Mean + SEM Range Mean ± SEM Range
1 8.7 ± 1.4 1.5-24.0 3.9 ± 0.6 1.5-10.4 19.8 + 2.6 0-41.1 6.9 ± 1.0 2.2-18.9
2 15.0 + 1.9 1.9-32.4 5.4 ± 0.7 1.5-13.1 56.5 ± 7.5 19.4-138.9 9.9 ± 1.5 2.6-26.7
3 14.6 ± 1.8 4.1-32.8 6.2 ± 1.6 1.4-27.8 40.7 + 1.7 27.5-54.3 8.9 ± 0.8 3.2-16.1
4 11.3 ± 1.2 2.3-20.7 5.0 ± 1.1 1.9-19.5 43.7 ± 5.1 14.6-96.1 9.6 ± 1.0 2.1-18.6
5 10.8 ± 1.5 0.7-25.1 4.2 ± 0.6 1.4-11.2 27.5 ± 6.0 2.8-98.8 7.7 ± 0.9 1.6-15.8
Total over
5 days 59.8 ± 5.0 16.0-96.7 28.9 ± 3.0 8.0-56.1 188.2 ± 17.1 74.5-348.4 43.0 ± 5.0 13.8-93.4
6 5.3 ± 3.1 1.8-11.0 2.6 ± 0.2 2.5-3.0 30.4 ± 8.3 20.7-44.8 9.1 + 3.2 5.7-15.0
7 4.9 ± 2.2 1.5-7.8 2.6 ± 0.3 2.1-2.9 30.0 ± 12.5 10.1-46.7 8.4 + 1.9 5.6-11.3
8 7.1 ± 2.5 3.3-10.6 2.5 ± 0.3 2.2-2.9 11.6 ± 2.5 7.3-14.4 4.0 ± 0.2 3.6-4.3
Total over
8 days 77.1 ± 27.4 45.6-125.7 36.6 ± 3.4 18.6-28.4 260.2 ± 8.7 211.4-236.7 64.5 ± 6.5 50.5-69.6
9 5.6 + 3.1 0.3-9.2 2.8 ± 0.5 2.1-3.1 6.7 ± 2.4 3.6-10.6 3.3 ± 0.7 2.5-4.5
10 8.4 ± 1.2 6.3-9.7 2.7 ± 0.2 2.4-2.9 7.7 ± 1.0 6.7-9.6 3.2 ± 0.6 2.4-4.0
11 4.6 ± 2.6 1.1-8.7 2.5 ± 0.2 2.1-2.8 9.1 ± 1.7 7.1-12.0 3.1 ± 0.2 2.7-3.3
12 4.3 ± 0.6 3.6-5.2 2.6 + 0.2 2.2-2.8 1.5 ± 0.2 1.3-1.8 2.5 ± 0.2 2.1-2.8
13 3.5 ± 2.2 0.9-7.3 2.5 ± 0.1 2.3-2.7 5.3 ± 1.6 2.7-7.4 2.5 ± 0.1 2.3-2.7
14 2.8 ± 0.7 2.2-4.1 2.2 ± 0.5 1.3-2.6 3.2 ± 2.3 0.4-7.1 2.3 ± 0.1 2.2-2.5
15 4.8 ± 0.6 4.1-5.9 2.5 ± 0.2 2.2-2.7 1.7 ± 1.0 0-2.9 2.3 ± 0.2 1.9-2.5
Total over
15 days 111.1 ± 36.4 45.6-151.2 50.3 ± 5.1 33.2-48.1 295.4 ± 9.7 245.7-273.8 79.9 ± 8.2 66.7-90.6
3a a 15.9
± 3.1 4.7-32.0 2.1
± 0.2 1.3-4.3 43.2
± 0.5 12.7-134.2 8.3 + 0.4 7.2-11.5
b 4.3 + 0.5 1.8-7.1 1.1 _ 0.1 0.7-1.5 27.0 ± 0.7 7.7-99.0 7.8 ± 0.7 3.4-10.8
c 5.0 ± 1.3 0.2-15.2 0.8 ± 0.1 0.5-1.3 25.8 _ 0.1 11.7-51.2 3.5 ± 0.3 2.5-5.2
aa, 8 days after first injection; b, 8 days after fifth injection; c, 8 days after tenth injection.
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Table 2. Total excretion ofbenzo[a]pyrene (BP) metabolites (,ug/kg
body weight) over 5 days after intraperitoneal injection of BP
(200 mg/kg) and tumor latency in rats.
Tumor
Urine Feces latency,
BP-7,8-diol 3-OH-BP BP-7,8-diol 3-OH-BP days
63.6 8.1 159.3 26.8 123
68.7 56.1 358.4 85.6 151
75.2 9.0 164.1 17.3 153
30.2 10.1 64.5 13.9 153
63.6 54.9 289.7 75.8 166
58.1 13.2 143.5 16.8 196
60.9 38.2 190.6 56.1 211
69.2 24.0 198.4 53.5 212
96.7 21.8 124.2 20.9 239
74.0 15.3 133.9 22.8 388
the limited number of observations; however, the proba-
bilities decreased proportionally with increases in total
excretion of BP-7,8-diol (Table 4). Thus, both statistical
approaches suggest that only the levels of BP-7,8-diol
excretedwithurine arecorrelated directlywiththelatency
oftumor appearance.
Conclusions and Future Perspectives
These comparative metabolic studies show significant
individual and species-specific variation inthe excretion of
carcinogenic activation and deactivation products ofBR It
is still unclear, however, whether these parameters ofBP
metabolism can be indicative of a high individual car-
cinogenic risk. Camus et al. (6) demonstrated that mice of
a strain responsive to the carcinogenic effect of BP pro-
duced larger quantities of total BP oxidized metabolites
and had a lower ratio of BP diols to oxidized metabolites
relative to mice ofa nonresponsive strain. Our experiment
in rats demonstrates that the indicative marker of indi-
vidual susceptibility to BP carcinogenesis is urinary
excretion ofBP-7,8-diol. This observation requires confir-
mation, which is the aim of our experiment with multiple
exposures to BP. Comparisons with other species, includ-
ingprimates,will allowbetterextrapolation ofanimal data
to the human situation.
The applicability of this approach for monitoring BP
metabolite excretion in humans is confirmed by our on-
going study, in which BP-7,8-diol and 3-OH-BP were
Table 3. Coefficients ofcorrelation between individual patterns ofexcretion ofbenzo[a]pyrene (BP) metabolites at
different intervals after exposure and tumor latency.
Linear model Y = a + bx Exponential model Y = exp (a + bx)
exposure, Urine Feces Urine Feces
days BP-7,8-diol 3-OH-BP BP-7,8-diol 3-OH-BP BP-7,8-diol 3-OH-BP BP-7,8-diol 3-OH-BP
1 -0.02 -0.05 +0.03 -0.23 +0.04 +0.02 +0.07 -0.21
2 +0.45 +0.05 -0.07 -0.21 +0.54 +0.13 -0.05 -0.21
3 -0.02 -0.19 +0.20 -0.05 -0.01 -0.17 +0.21 +0.05
4 +0.19 -0.11 -0.42 -0.27 +0.09 -0.08 -0.43 -0.23
5 +0.37 -0.13 -0.42 -0.18 +0.44 -0.05 -0.42 -0.12
1+2 +0.40 +0.22 -0.06 -0.22 +0.50 +0.10 -0.03 -0.21
1+2+3 +0.36 -0.12 -0.01 -0.17 +0.46 -0.06 +0.02 -0.15
1+2+3+4 +0.40 -0.12 -0.17 -0.20 +0.43 -0.07 -0.15 -0.18
1+2+3+4+5 +0.42 -0.12 -0.26 -0.21 +0.47 -0.07 -0.25 -0.17 Table 4. Probability of tumor development in rats with different
levels ofexcretion ofbenzo[alpyrene-7,8-diol in urine.
Days after Level of excretion (pg/kg body weight)
exposure <60 60-70 >70
0-130 0.33 0.00 0.00
0-160 0.67 0.25 0.33
0-190 0.67 0.50 0.33
0-210 1.00 0.50 0.33
0-240 1.00 1.00 0.67
0-390 1.00 1.00 1.00
detected in the urine of lung cancer patients who were
heavysmokers atconcentrations comparablewiththose in
theratsinthe studydescribed above.Assumingthat DNA
adduct formation and repair are the most reliable predic-
torsofcarcinogenicrisk (10),wearecomparingtheirlevels
inliver ofrats exposed to BPwith levels ofBPmetabolites
in the urine ofthe same animals.
Individual markers of susceptibility to various car-
cinogens couldberecognized atanystage ofcarcinogenesis.
Mostmarkers are associatedwiththeinitiation stage; itwill
beusefultoidentifypossiblemarkersofthepromotion stage
ofcarcinogenesis.
This manuscript was presented as a poster at the Conference on
Biomonitoring and Susceptibility Markers in Human Cancer: Applica-
tions in Molecular Epidemiology and Risk Assessment that was held in
Kailua-Kona, Hawaii, 26 October-1 November 1991.
We are indebted to 0. Nepomynaschaya for excellent technical
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